Alvotech (NASDAQ:ALVO - Get Free Report) is projected to post its Q4 2025 results after the market closes on Wednesday, March 18th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $162.1950 million for the quarter. Parties are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 19, 2026 at 8:00 AM ET.

Alvotech Trading Down 3.5%

• Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem

Shares of NASDAQ:ALVO opened at $3.88 on Wednesday. The firm has a market capitalization of $1.17 billion, a PE ratio of 16.87 and a beta of 0.16. Alvotech has a 1-year low of $3.65 and a 1-year high of $11.85. The business's 50 day moving average is $4.72 and its 200-day moving average is $6.09.

Analysts Set New Price Targets

Several research analysts recently commented on the company. UBS Group reduced their target price on Alvotech from $13.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, November 18th. Barclays started coverage on shares of Alvotech in a report on Monday, December 8th. They issued an "underweight" rating and a $5.00 price target on the stock. Wall Street Zen downgraded shares of Alvotech from a "hold" rating to a "sell" rating in a report on Saturday, November 22nd. Zacks Research lowered shares of Alvotech from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 18th. Finally, Morgan Stanley set a $10.00 target price on shares of Alvotech in a research note on Wednesday, December 3rd. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $8.60.

• 2 Generic Drug Makers With Growing Runways

Read Our Latest Analysis on Alvotech

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Alvotech by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company's stock worth $35,481,000 after purchasing an additional 114,255 shares during the last quarter. Millennium Management LLC lifted its holdings in Alvotech by 1,707.7% during the 4th quarter. Millennium Management LLC now owns 357,176 shares of the company's stock valued at $1,832,000 after purchasing an additional 337,417 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Alvotech by 88.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company's stock valued at $1,331,000 after buying an additional 122,089 shares in the last quarter. Geode Capital Management LLC boosted its position in Alvotech by 10.7% in the fourth quarter. Geode Capital Management LLC now owns 254,921 shares of the company's stock valued at $1,308,000 after buying an additional 24,667 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC bought a new stake in Alvotech during the second quarter worth about $1,782,000.

Alvotech Company Profile

(Get Free Report)

Alvotech NASDAQ: ALVO is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).

See Also

• Five stocks we like better than Alvotech
• The gold chart Wall Street is terrified of…
• What a Former CIA Agent Knows About the Coming Collapse
• Elon Musk already made me a “wealthy man”
• Unlocked: Elon Musk’s Next Big IPO
• 1,500 Banks Just Handed the Fed Your Bank Account

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alvotech Right Now?

Before you consider Alvotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list.

While Alvotech currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here